Gritsaev S V, Shikhbabaeva D I, Rybakova L P, Sergeev A N, Kapustin S I, Abdulkadyrov K M
Ter Arkh. 2013;85(6):60-5.
To study an association between iron metabolism, free radical oxidation (FRO), and antioxidative system (AOS) in patients with acute myeloid leukemia (AML) during intensive chemotherapy.
AML patients (n = 14) with a median age of 46 years received 7+3 courses (n = 3) containing cytarabine > or = 1 g/m2/introduction (n = 8) and myeloablative conditioning regimen before hematopoietic stem cell transplantation (n = 3). The concentrations of iron, ferritin, transferrin saturation (TFS), and malonic dialdehyde and the activity of superoxide dismutase (SOD), ceruloplasmin (CP), and catalase were investigated in their sera. The investigations were performed before and after chemotherapy and during hemopoietic recovery and rehospitalization. RESULTS; After therapy termination, there was a significant increase in TFS (6.8% vs 41.9%; p < 0.0001), which gave way to its reduction during hemopoietic recovery (89.5% vs 96.8%; p = 0.003). The activity of antioxidant enzymes was found to be altered at a time. That of catalase was enhanced throughout cytopenia (3.8 and 3.3 vs 5.7 conventional units (CU)/ml; p = 0.028 and p = 0.011). The lower activity of SOD (21.0 vs 41.0 CU/ml; p = 0.018) and the higher activity of CP (1.1 vs 0.8 g/l) were ascertained when leukocyte count increased up to > or = 1 x 10(9)/l.
After intensive cytostatic therapy, there was a phasic TFS increase accompanied by the compensatory change in AOS activity, which is aimed at neutralizing FRO products.
研究急性髓系白血病（AML）患者在强化化疗期间铁代谢、自由基氧化（FRO）与抗氧化系统（AOS）之间的关联。
14例AML患者，中位年龄46岁，接受7+3疗程（n = 3），其中阿糖胞苷剂量≥1 g/m²/次（n = 8），3例患者在造血干细胞移植前接受清髓预处理方案。检测患者血清中铁、铁蛋白、转铁蛋白饱和度（TFS）、丙二醛浓度以及超氧化物歧化酶（SOD）、铜蓝蛋白（CP）和过氧化氢酶活性。在化疗前后、造血恢复及再次住院期间进行检测。结果：治疗结束后，TFS显著升高（6.8%对41.9%；p < 0.0001），而在造血恢复期间TFS下降（89.5%对96.8%；p = 0.003）。同时发现抗氧化酶活性发生改变。在全血细胞减少期间，过氧化氢酶活性增强（3.8和3.3对5.7传统单位（CU）/ml；p = 0.028和p = 0.011）。当白细胞计数升至≥1×10⁹/L时，SOD活性降低（21.0对41.0 CU/ml；p = 0.018），CP活性升高（1.1对0.8 g/L）。
强化细胞毒性治疗后，TFS呈阶段性升高，同时AOS活性发生代偿性变化，旨在中和FRO产物。
